Sosič Izidor, Mitrović Ana, Ćurić Hrvoje, Knez Damijan, Brodnik Žugelj Helena, Štefane Bogdan, Kos Janko, Gobec Stanislav
Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000 Ljubljana, Slovenia.
Faculty of Chemistry and Chemical Technology, University of Ljubljana, Večna pot 113, 1000 Ljubljana, Slovenia.
Bioorg Med Chem Lett. 2018 Apr 15;28(7):1239-1247. doi: 10.1016/j.bmcl.2018.02.042. Epub 2018 Feb 23.
Human cathepsin B is a cysteine protease with many house-keeping functions, such as intracellular proteolysis within lysosomes. Its increased activity and expression have been strongly associated with many pathological processes, including cancers. We present here the design and synthesis of novel derivatives of nitroxoline as inhibitors of cathepsin B. These were prepared either by omitting the pyridine part, or by modifying positions 2, 7, and 8 of nitroxoline. All compounds were evaluated for their ability to inhibit endopeptidase and exopeptidase activities of cathepsin B. For the most promising inhibitors, the ability to reduce extracellular and intracellular collagen IV degradation was determined, followed by their evaluation in cell-based in vitro models of tumor invasion. The presented data show that we have further defined the structural requirements for cathepsin B inhibition by nitroxoline derivatives and provided additional knowledge that could lead to non-peptidic compounds with usefulness against tumor progression.
人组织蛋白酶B是一种具有多种管家功能的半胱氨酸蛋白酶,如在溶酶体内进行细胞内蛋白水解。其活性和表达的增加与包括癌症在内的许多病理过程密切相关。我们在此展示了新型硝氧喹啉衍生物作为组织蛋白酶B抑制剂的设计与合成。这些衍生物要么通过省略吡啶部分制备,要么通过修饰硝氧喹啉的2、7和8位来制备。评估了所有化合物抑制组织蛋白酶B内肽酶和外肽酶活性的能力。对于最有前景的抑制剂,测定了其降低细胞外和细胞内IV型胶原降解的能力,随后在基于细胞的肿瘤侵袭体外模型中对其进行评估。所呈现的数据表明,我们进一步明确了硝氧喹啉衍生物抑制组织蛋白酶B的结构要求,并提供了可能导致对肿瘤进展有效的非肽类化合物的更多知识。